ATx08 001

Drug Profile

ATx08 001

Alternative Names: ATx08-001; FK 614

Latest Information Update: 13 Aug 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Astellas Pharma
  • Developer Aestus Therapeutics; Astellas Pharma
  • Class Antihyperglycaemics; Benzimidazoles; Small molecules
  • Mechanism of Action Peroxisome proliferator-activated receptor gamma agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Postherpetic neuralgia
  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 13 Aug 2015 No recent reports on development identified - Phase-II for Postherpetic neuralgia in USA (PO)
  • 15 Dec 2011 Safety and efficacy data from a phase II trial in Postherpetic neuralgia released by Aestus Therapeutics
  • 19 Aug 2011 Aestus completes a phase II trial in Postherpetic Neuralgia in US (NCT01318226)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top